ezetimibe add-on to statin for effectiveness (EASE) trial
Jump to navigation
Jump to search
Introduction
Study characteristics:
- community based, manufacturer sponsored, randomized trial
- 3 of 6 authors employed by sponsor
3030 patients on statins at start of study
- largely atorvastatin, pravastatin, simvastatin 10-40 mg QD
- at least 6 weeks of statin therapy prior to start of study
- patients had not reached NCEP LDL cholesterol target levels
- mean LDL cholesterol = 129 mg/dL on statin monotherapy
Treatment:
Results: (after 6 weeks)
- LDL cholesterol decreased 26% in the ezetimibe group vs 3% in the placebo group
- NCEP LDL cholesterol target levels reached by 71% of ezetimibe group vs 21% of target group
- no serious adverse effects reported
More general terms
Additional terms
References
- ↑ Journal Watch 25(13):104, 2005 Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc. 2005 May;80(5):587-95. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15887425
Hurley DL, Isley WL. Getting there: statin plus ezetimibe for low-density lipoprotein cholesterol goals. Mayo Clin Proc. 2005 May;80(5):585-6. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15887424